Related Experiment Video
Updated: Jan 2, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.1K
Systematic Approach for Drug Repositioning of Anti-Epileptic Drugs.
Younhee Ko1, Chulho Lee2, Youngmok Lee3
1Division of Biomedical Engineering, Hankuk University of Foreign Studies, Kyoungki-do 17035, Korea.
Diagnostics (Basel, Switzerland)
|December 6, 2019
Summary
New research reveals that many intractable epilepsy cases stem from genetic causes not targeted by current antiepileptic drugs (AEDs). This finding opens avenues for novel drug repositioning to treat refractory epilepsy.
Area of Science:
- Neurology
- Pharmacogenomics
- Systems Biology
Background:
- Epilepsy is a common neurological disorder characterized by unpredictable seizures.
- Despite advances in antiepileptic drugs (AEDs), 20-30% of patients experience intractable or uncontrolled seizures.
- Identifying novel therapeutic targets is crucial for refractory epilepsy.
Purpose of the Study:
- To investigate the genetic basis of intractable epilepsy.
- To explore the relationship between causative genes and existing AED targets.
- To identify potential new drug targets for refractory epilepsy through network analysis.
Main Methods:
- Construction of an epilepsy drug-target network (EDT).
- Identification of causative genes in 60 epilepsy patients.
- Analysis of gene-target interactions and functional networks.
- Comparison of causative genes with existing AED targets.
Main Results:
- Causative genes in most intractable epilepsy patients were not targeted by current AEDs.
- These genes were functionally distant from the mechanisms of existing AEDs.
- The study identified potential new drug targets for refractory epilepsy.
Conclusions:
- Existing AEDs are ineffective for a significant portion of epilepsy patients due to targeting different etiological mechanisms.
- Novel therapeutic strategies targeting identified causative genes are needed for refractory epilepsy.
- Drug repositioning, informed by integrated drug-target and functional networks, offers a promising approach for developing new epilepsy treatments.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.4K
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
1.2K
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
01:20Antiepileptic Drugs: Potassium Channel Activators
568
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
568
01:14Antiepileptic Drugs: Glutamate Antagonists
829
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
829
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
762
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
762